NASDAQ:ENDP - Endo International Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $10.51 +0.17 (+1.64 %) (As of 02/22/2019 04:00 PM ET)Previous Close$10.51Today's Range$10.34 - $10.6752-Week Range$5.27 - $18.50Volume1.50 million shsAverage Volume1.91 million shsMarket Capitalization$2.36 billionP/E Ratio3.55Dividend YieldN/ABeta1.28 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. Receive ENDP News and Ratings via Email Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ENDP Previous Symbol CUSIP29264F20 CIK1593034 Webwww.endo.com Phone011-353-1268-2000Debt Debt-to-Equity RatioN/A Current Ratio1.13 Quick Ratio0.96Price-To-Earnings Trailing P/E Ratio3.55 Forward P/E Ratio3.85 P/E Growth3.88 Sales & Book Value Annual Sales$3.47 billion Price / Sales0.68 Cash Flow$8.4758 per share Price / Cash Flow1.24 Book Value$2.17 per share Price / Book4.84Profitability EPS (Most Recent Fiscal Year)$3.84 Net Income$-2,035,430,000.00 Net Margins-37.82% Return on Equity1,348.52% Return on Assets6.02%Miscellaneous Employees3,039 Outstanding Shares224,350,000Market Cap$2.36 billion Next Earnings Date2/28/2019 (Confirmed) OptionableOptionable Endo International (NASDAQ:ENDP) Frequently Asked Questions What is Endo International's stock symbol? Endo International trades on the NASDAQ under the ticker symbol "ENDP." How were Endo International's earnings last quarter? Endo International PLC (NASDAQ:ENDP) posted its quarterly earnings data on Wednesday, August, 8th. The company reported $0.76 EPS for the quarter, topping the consensus estimate of $0.54 by $0.22. The business had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. Endo International had a negative net margin of 37.82% and a positive return on equity of 1,348.52%. Endo International's quarterly revenue was down 18.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.93 earnings per share. View Endo International's Earnings History. When is Endo International's next earnings date? Endo International is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for Endo International. What price target have analysts set for ENDP? 17 brokerages have issued 12-month target prices for Endo International's shares. Their predictions range from $9.00 to $26.00. On average, they expect Endo International's share price to reach $16.0714 in the next twelve months. This suggests a possible upside of 52.9% from the stock's current price. View Analyst Price Targets for Endo International. What is the consensus analysts' recommendation for Endo International? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 12 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International. What are Wall Street analysts saying about Endo International stock? Here are some recent quotes from research analysts about Endo International stock: 1. According to Zacks Investment Research, "Endo is in the process of redefining its business, given the persistent decline in the generic business which is facing challenges. The focus now is on sterile injectables and Xiaflex. Demand for Xiaflex continues to be strong owing to high demand driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Moreover, Endo has centralized and streamlined its global supply chain, quality and compliance organization in order to create a more cohesive and efficient structure to support both its generics and branded businesses. Endo is working to expand the drug’s label. However, huge level of debt is a concern. Moreover, response rates from the CCH trials weren’t impressive either. Shares have underperformed the industry in the past six months. Estimates for Q4 are down by a cent in the last 30 days. Endo's track record is impressive though with positive earnings surprises in last four quarters." (2/13/2019) 2. Canaccord Genuity analysts commented, "We view Athenex’s compounded vasopressin launch today as more headline risk than an actual financial hit to Endo’s near-term results. We expect Endo to restart litigation with FDA regarding compounding guidance and we’d also expect patent litigation against Athenex that could potentially enjoin sales of the compounded product. While ENDP shares have had strong momentum of late, we remain concerned that little events like these – along with broader opioid and product litigation – could dent that momentum. As such, we maintain our HOLD rating on ENDP shares." (8/13/2018) 3. Cantor Fitzgerald analysts commented, ". We are raising our 12 month PT for ENDP shares to $12 from $7. The increase in our PT is driven by multiple expansion (from 8x to 9x 2019 EV/EBITDA versus 10x for the comps). We think this is deserved since generic drug pricing has stabilized for ENDP, according to the company, and we are optimistic that ENDP could report positive data for CCH to treat cellulite as early as the end of this year versus its official guidance of 2019. The following points support our view." (7/23/2018) Has Endo International been receiving favorable news coverage? News articles about ENDP stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Endo International earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. Are investors shorting Endo International? Endo International saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 16,449,204 shares, a decline of 12.3% from the January 15th total of 18,757,451 shares. Based on an average trading volume of 2,763,492 shares, the days-to-cover ratio is presently 6.0 days. Currently, 8.2% of the company's shares are sold short. View Endo International's Current Options Chain. Who are some of Endo International's key competitors? Some companies that are related to Endo International include Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), Nektar Therapeutics (NKTR), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Amarin (AMRN) and United Therapeutics (UTHR). What other stocks do shareholders of Endo International own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endo International investors own include Bausch Health Companies (BHC), General Electric (GE), NVIDIA (NVDA), Gilead Sciences (GILD), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Bank of America (BAC) and Celgene (CELG). Who are Endo International's key executives? Endo International's management team includes the folowing people: Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)Mr. Blaise Coleman, Exec. VP & CFO (Age 45)Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62) Who are Endo International's major shareholders? Endo International's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.13%), Geode Capital Management LLC (1.09%), Connor Clark & Lunn Investment Management Ltd. (0.68%), Diamond Hill Capital Management Inc. (0.58%), Canada Pension Plan Investment Board (0.33%) and Tekla Capital Management LLC (0.32%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Terrance J Coughlin and William P Montague. View Institutional Ownership Trends for Endo International. Which major investors are selling Endo International stock? ENDP stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, River & Mercantile Asset Management LLP, Commonwealth Bank of Australia, Geode Capital Management LLC, Gabelli Funds LLC, New York State Teachers Retirement System, Connor Clark & Lunn Investment Management Ltd. and Affinity Investment Advisors LLC. Company insiders that have sold Endo International company stock in the last year include Nancy J Hutson, Roger H Kimmel and William P Montague. View Insider Buying and Selling for Endo International. Which major investors are buying Endo International stock? ENDP stock was purchased by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Oregon Public Employees Retirement Fund, Diamond Hill Capital Management Inc., Bowling Portfolio Management LLC, Rhumbline Advisers, Oregon Public Employees Retirement Fund, LMR Partners LLP and Municipal Employees Retirement System of Michigan. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International. How do I buy shares of Endo International? Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Endo International's stock price today? One share of ENDP stock can currently be purchased for approximately $10.51. How big of a company is Endo International? Endo International has a market capitalization of $2.36 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe. What is Endo International's official website? The official website for Endo International is http://www.endo.com. How can I contact Endo International? Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected] MarketBeat Community Rating for Endo International (NASDAQ ENDP)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 844 (Vote Outperform)Underperform Votes: 693 (Vote Underperform)Total Votes: 1,537MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/23/2019 by MarketBeat.com StaffFeatured Article: What are earnings reports?